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Abstract
Background: Polyglutamine (polyQ)-induced protein aggregation is the hallmark of a group of neurodegenerative diseases,
including Huntington’s disease. We hypothesized that a protease that could cleave polyQ stretches would intervene in the
initial events leading to pathogenesis in these diseases. To prove this concept, we aimed to generate a protease possessing
substrate specificity for polyQ stretches.
Methodology/Principal Findings: Hepatitis A virus (HAV) 3C protease (3CP) was subjected to engineering using a yeast-
based method known as the Genetic Assay for Site-specific Proteolysis (GASP). Analysis of the substrate specificity revealed
that 3CP can cleave substrates containing glutamine at positions P5, P4, P3, P1, P29,o rP 3 9, but not substrates containing
glutamine at the P2 or P19 positions. To accommodate glutamine at P2 and P19, key residues comprising the active sites of
the S2 or S19 pockets were separately randomized and screened. The resulting sets of variants were combined by shuffling
and further subjected to two rounds of randomization and screening using a substrate containing glutamines from
positions P5 through P39. One of the selected variants (Var26) reduced the expression level and aggregation of a huntingtin
exon1-GFP fusion protein containing a pathogenic polyQ stretch (HttEx1(97Q)-GFP) in the neuroblastoma cell line SH-SY5Y.
Var26 also prevented cell death and caspase 3 activation induced by HttEx1(97Q)-GFP. These protective effects of Var26
were proteolytic activity-dependent.
Conclusions/Significance: These data provide a proof-of-concept that proteolytic cleavage of polyQ stretches could be an
effective modality for the treatment of polyQ diseases.
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Introduction
The aggregation of polyglutamine (polyQ) proteins within
neuronal cells has been implicated in the pathogenesis of a group
of neurodegenerative disorders, including Huntington’s disease
(HD) [1,2]. The toxicity of aggregates in neurons is attributed to
altered proteasomal functions [3,4] and/or to the sequestration of
vital cellular proteins such as transcriptional elements [5],
molecular chaperons [6], cytoskeletal proteins [7], and compo-
nents of the ubiquitin-proteasome system. Therefore, aggregation
of polyQ proteins is widely thought of as an attractive therapeutic
target.
Various interventions have been shown to be effective in
inhibiting polyQ protein aggregation and thereby, in reducing the
toxicity of these proteins in cultured cells and animal models.
Small peptides, referred to as glutamine binding peptides (QBP)
that preferentially bind to pathogenic polyQ stretches were
identified by screening a combinatorial peptide library. It was
also shown that the expression of QBP tandem repeats in cultured
cells inhibits polyQ-induced cell death [8]. In another study,
suppressor polypeptides with a flexible helix spacer sequence
flanked by two 25Q sequences were found to be effective in
Drosophila models of HD [9]. Small chemical compounds isolated
from yeast-based high throughput screens potently inhibited
polyQ aggregation in brain slice cultures and other cell-based
models [10]. A number of chemical compounds, such as Congo
Red, Thioflavin S, Chrysamine G, and Direct Fast Yellow, have
also been shown to inhibit polyQ aggregation [11]. In addition,
there are reports claiming the effective use of intracellular
antibodies that specifically bind to elongated polyQ chains in
HD models [11,12,13,]. Finally, over-expression of molecular
chaperons, such as Hsp70 and Hsp40, in cellular and Drosophila
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consequentially prevented neurodegeneration [14,15]. These
compounds and molecules may block aggregation by selectively
binding to and stabilizing the native conformation of the elongated
polyQ tract.
We hypothesized that the proteolytic cleavage of pathogenic
polyQ stretches would help reduce the level of aggregation by
shortening the pathogenic polyQ stretch to a non-pathogenic
length, thereby greatly reducing the complications induced by
polyQ proteins. Since no protease is known to cleave polyQ
stretches, we decided to adopt a directed evolution approach to
generate a polyQ-specific protease. The polyprotein processing of
members of the picornaviridae family of viruses, which includes
Hepatitis A virus (HAV), is mainly mediated by the 3C proteases
(3CP). These proteases show a unique substrate specificity
preference for a glutamine residue at the P1 site. We have
previously utilized a yeast-based screening method, referred to as
the Genetic Assay for Site-specific Proteolysis (GASP), to produce
an engineered variant of HAV 3CP that can cleave a peptide
substrate containing glutamine at the P19 site more efficiently than
its original substrate [16]. Motivated by this earlier success, we
further extended the use of GASP to generate a polyQ-specific
protease (PQP) using directed evolution approach. The results of
this study clearly validate our screening methodology and our
PQP development approach. This study also shows that one of the
selected variants (Var26) prevents polyQ protein aggregation and
attenuates polyQ-induced cytotoxicity. These data provide a
proof-of-concept that proteolytic cleavage of polyQ stretches may
be a valuable strategy for the treatment of polyQ diseases.
Results
Glutamine scanning of the HAV 3C protease
The principle underlying GASP was previously published and is
illustrated in Fig. 1A. Cleavage in the substrate site of a
membrane-anchored fusion protein (STE2-substrate-LexA-b42)
induces the release of the LexA-b42 moiety from the plasma
membrane and activates the expression of the reporter genes, Leu2
and LacZ. Protease expression is under the control of the Gal1
promoter and is, thus induced by the addition of galactoseto the
media. Growth on selective plates and formation of a blue color on
X-gal plates indicates site-specific proteolysis. Using this method,
the ability of the HAV 3C protease (3CP) to cleave substrates
containing glutamine substituted at different sites was analyzed.
Substrate linker oligonucleotides encoding the wild-type (WT)
substrate sequence (ELRTQQSFS) and mutated substrate
sequences (P5-Q , P39-Q) in which glutamine residues replaced
the native residues from P5 through P3’ (Table S1) were prepared
and cloned into the pADH-Ste2-Lex vector. Each of these
substrate vectors was transformed, along with the protease vector,
pGAL-3CP, into the yeast strain EGY48. The results from the
selective plates and the X-gal plates suggested that glutamine is
tolerated at the P5, P4, P3, P1, P29, and P39, but not at the P2 and
P19 positions (Fig. 1B). An oligonucleotide encoding a substrate
(P5-39Q(TS)) containing glutamine residues at all sites except the
P2 and P19 positions (QQQTQQSQQ) was then prepared. This
substrate was cleaved by 3CP (Fig. 1B). Therefore, the S2 and S19
pockets were subjected to further engineering to generate PQP.
Engineering at the S2 pocket
In a prior study, we had engineered the S2 pocket of 3CP and
generated a number of variants [16]. From this group, 12 variants
were selected that contained mutations at amino acids 145, 146,
147, and 155. This work revealed two key points: first, mutating the
29
th amino acid is critical for the glutamine accomodation in the S2
pocket; and second, the amino acid 155 is favored by the original
leucine. Therefore, we decided to include M29 and exclude L155
for additional mutation screening. In addition, the V28 residue was
also included because it is close to M29 and appears to play a role in
constituting the S2 pocket based on the 3CP crystal structure. Since
the resulting complexity would be too large if all of the five target
residues were randomized at once, we decided to perform
randomized mutagenesis of four residues at a time, V28/M29/
H145/K146 and M29/H145/K146/K147. These residues were
Figure 1. Principle of GASP. A. A fusion protein containing the Ste2
transmembrane domain followed by a polyQ substrate linker and a
LexA-b42 transcription factor was expressed in yeast EGY48 cells using a
constitutive ADH promoter. Co-expression of galactose-inducible WT
HAV 3CP does not result in cleavage of the polyQ substrate sequence
(upper panel), while a conceptual 3CP variant cleaves the polyQ linker,
causing the release of the transcription factor from the membrane,
which in turn activates the reporter genes, Leu2 and LacZ (lower panel).
B. EGY48 cells were transformed with pGAL-HAV3CP and pADH-Ste2-
Substrate-Lex in which glutamine is substituted in the P5-P39 positions
of the 3CP substrate sequence (see Table S1). Cleavage of the indicated
substrate sequence was evident by the growth of yeast cells in leucine-
deficient medium and the formation of a blue color on X-gal medium.
doi:10.1371/journal.pone.0022554.g001
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activity using the P2-Q substrate (ELRQQQSFS). From these
separate screens, 23 and 19 variants were obtained, respectively
(Tables S2 and S3).
Engineering at the S19 pocket
A close examination of the 3CP crystal structure suggested that
three amino acids (L168/P169/L199) might constitute the S19
pocket. These residues were randomly mutated by successive
PCR. The resulting mutant library was screened for proteolytic
activity using the P19-Q substrate (ELRTQQQFS). Twenty
positive clones were selected based on colony growth on selective
plates and blue color formation on X-gal plates (Table S4).
Combining the S2 and S19 pocket variants
The individually selected variants from S2 pocket and S19
pocket engineering cleaved the P2-Q and P19-Q substrates
respectively, but none of the selected variants could cleave the
polyQ substrate (data not shown). Therefore, the variants from the
four independent screenings were combined by shuffling to
generate a pool of variants that contained various mutations in
both the S2 and S19 pockets (Fig. 2). The resulting library was
screened using the Q8 substrate (QQQQQQQQQ), which
contains glutamine at all eight sites, and eleven positive clones
were selected (Table S5). All the selected variants appeared to have
relatively low proteolytic activity, as the colonies grew slowly on
selective plates and produced a faint blue color on X-gal plates
(data not shown). These eleven candidate clones were pooled
together and were used as template for further mutagenesis by
error prone PCR and DNA shuffling. After two rounds of
mutagenesis and selection, 44 variants that appeared to have
moderate proteolytic activity against the Q8 substrate were finally
obtained (Table S6). The clone that appeared to have the highest
proteolytic activity, variant 26 (Var26), was tested for its effects in
an in vitro model of HD.
Var26 prevents aggregation of polyQ proteins
Both WT 3CP and Var26 cleaved the WT substrate but only
Var26 cleaved the Q8 substrate in yeast as assessed by GASP
(Fig. 3A). A C172A mutant of Var26 was generated in which the
catalytic cystein
172 nucleophile was mutated to alanine [17,18,
19,20]. C172A did not cleave the Q8 substrate, indicating that the
cleavage of the Q8 substrate in yeast requires the proteolytic
activity of Var26 (Fig. 3A). These data showed that Var26
acquired a relaxed rather than an altered substrate specificity.
Yeast cells were transformed with a Q8 substrate-expression
vector along with WT 3CP-, Var26-, or C172A-expressing
vectors. Protein extracts were blotted and probed with an anti-
LexA antibody to detect the full-length STE2-substrate-LexA-b42
fusion protein. Without protease expression induction (glucose), no
Figure 2. Engineering scheme for the isolation of polyQ cleaving variants. Screening of the S2 pocket variants for P2-Q cleavage yielded 54
positive candidates (12 from HKKL, 23 from VMHK, and 19 from MHKK libraries). Screening of the S1’ pocket variants for P1’-Q cleavage resulted in 23
clones from the LPL library. These variants were combined through shuffling to generate a pool of variants in which each protease possesses S2 as
well as S1’ pocket mutations. These variants were then screened for Q8 substrate cleavage yielding 11 candidates with low activity. These mutants
were further subjected to two rounds of error prone PCR and shuffling coupled with selection through GASP to generate 44 variants with moderate
activity.
doi:10.1371/journal.pone.0022554.g002
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expression of the protease was induced (galactose), Var26, but not
WT 3CP or C172A, significantly reduced the amounts of the full-
length fusion protein (Fig. 3B), which confirmed our GASP results.
SH-SY5Y [21], a human neuroblastoma cell line, was then
transfected with plasmids encoding a human huntingtin (Htt)
exon1-GFP fusion protein containing either a non-pathogenic
stretch (25Q) of glutamines (HttEx1(25Q)-GFP) or a pathogenic
stretch (97Q) of glutamines (HttEx1(97Q)-GFP) along with the
protease expression plasmids. None of the tested proteases affected
the expression level of HttEx1(25Q)-GFP, but Var26 significantly
reduced the levels of HttEx1(97Q)(Fig. 3C). This result indicates
that Var26 effectively cleaves the polyQ stretch in HttEx1(97Q)-
GFP in mammalian cells. It was surprising that Var26 did not
cleave the polyQ stretch in HttEx1(25Q)-GFP. It may be possible
that these two polyQ stretches adopt different conformations.
Aggregation of the HttEx1-GFP fusion proteins was observed
under a fluorescent microscope. Consistent with previous reports,
no aggregation was observed with HttEx1(25Q)-GFP but
significant aggregation was observed with HttEx1(97Q)-GFP. This
protein aggregation was significantly blocked by Var26 but not by
WT 3CP or C172A (Fig. 4A). This result indicates that cleavage of
the polyQ stretch by Var26 leads to the dispersion of the resulting
carboxy-terminus of the fusion protein. To test whether the
amino-terminal fragment of the fusion protein that results from
Var26-mediated cleavage is also dispersed, immunostaining was
performed with the antibody HP12, which is specific for the
amino-terminal 17 amino acids of Htt. The aggregation of the
amino-terminal fragments was also significantly blocked. More-
over, HP12 immunofluorescence was indistinguishable from GFP
fluorescence in all of the cells observed (Fig. 4B). This result
indicates that the cleavage of HttEx1(97Q)-GFP by Var26 reduced
aggregation of the fusion protein.
Var26 prevents polyQ-mediated cytotoxicity
HttEx1(97Q)-GFP induced significant SH-SY5Y cell death as
assessed by Trypan blue staining, which was greatly reduced by
Var26 but not by WT 3CP or C172A (Fig. 5A). Further, in a
Figure 3. Var26 cleaves polyQ stretches. A. Yeast EGY48 cells containing either an empty vector (Vec), pGAL-3CP (WT), pGAL-Var26 (Var26), or
pGAL-C172A (C172A) plasmids, together with pADH-Ste2-2B/2C-Lex (WT substrate) or pADH-Ste2-Q8-Lex vectors (Q8 substrate) were plated on
leucine-lacking plates and X-gal plates containing either glucose or galactose. B. The pADH-Ste2-Q8-Lex vector was co-transformed with an empty
vector (Vec), or pGAL-3CP (WT), pGAL-Var26 (Var26), or pGAL-C172A (C172A) plasmids into EGY48 yeast cells and grown in inducible (galactose) or
non-inducible (glucose) medium. After 16 hours of incubation, cells were lysed, separated by SDS-PAGE, and blotted and probed with anti-LexA
antibody. C. SH-SY5Y cells were transfected with pcDNA-HttEx1(25Q) or (97Q)-GFP together with an empty vector (Vec) or, pcDNA3-WT 3CP (WT),
pcDNA3-Var26 (Var26), or pcDNA3-C172A (C172A) plasmids. Cell lysates were separated by SDS-PAGE, blotted, and probed with an anti-huntingtin
antibody. GAPDH was used as a loading control. The expression ratio of HttEx1 and GAPDH was calculated using computer-assisted image analysis.
Error bars represent the SD. Significance was determined by student’s t test. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0022554.g003
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alone did not significantly affect the viability of the cells (see Fig.
S1). Cell death can also be monitored by nucleus fragmentation
and condensation, a phenomenon known as pyknosis. Consistent
with previous reports [22], HttEx1(97Q)-GFP induced pyknosis in
cells both with and without aggregation. Var26 significantly
reduced the number of pyknotic cells in the presence or absence of
aggregation, but WT 3CP or C172A did not (Fig. 5B). Caspase 3 is
an execution caspase mediating apoptosis. HttEx1(97Q)-GFP
elevated the level of active caspase-3, which was significantly
suppressed by Var26 but not by WT 3CP or C172A (Fig. 5C).
These results indicate that Var26 inhibits polyQ-induced cell
death in SH-SY5Y cells in a proteolytic activity-dependent
manner.
Discussion
A group of neuronal diseases are caused by the accumulation
and/or aggregation of amyloidogenic proteins. For example, a
primary cause of Alzheimer’s diseases (AD) is thought to be the
accumulation of a short peptide called amyloid-b (Ab) in the brain.
Elevated degradation of Ab by an endogenous protease, such as
neprilysin [23,24], or a viral protease, such as turnip mosaic virus
(TuMV) NIa [25], alleviated AD-associated symptoms in animal
models. These findings lead us to hypothesize that proteolytic
cleavage of polyQ stretches would be a valid approach for the
treatment of polyQ diseases. Since no protease was known to
cleave polyQ stretches, we decided to generate one using a
combination of rational design and directed evolution approaches.
We started protein engineering with several viral proteases,
including the 3C proteases (3CP) of mengovirus, coxsackievirus,
and hepatitis A virus (HAV). One important feature shared by
these proteases is that they cleave peptide bonds after glutamine.
Our preliminary studies revealed that mengovirus and coxsackie-
virus 3CPs strictly favored a proline residue at their P29 sites, while
HAV 3CP virtually favored any amino acid at the P29 position.
Due to its leniency in substrate requirement, HAV 3CP was
utilized for further engineering. The glutamine scanning experi-
Figure 4. Var26 prevents polyQ aggregation. A. SH-SY5Y cells were cotransfected with pcDNA-HttEx1(25Q) or (97Q)-GFP together with an
empty vector (Vec) or, pcDNA3-WT 3CP (WT), pcDNA3-Var26 (Var26), or pcDNA3-C172A (C172A). After 48hrs of incubation, the cells were fixed and
observed under a fluorescence microscope. The percentage of GFP-aggregation positive cells was plotted (n=3). Error bars represent the SD.
Significance was determined by student’s t test. *p,0.05, **p,0.01. B. SH-SY5Y cells were treated as in panel A. After 48hrs of incubation, the cells
were fixed and immunostained with the HP12 antibody. The percentage of cells containing amino-terminal aggregation was plotted (n=4). Error bars
represent the SD. Significance was determined by student’s t test. **p,0.01.
doi:10.1371/journal.pone.0022554.g004
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glutamine residues, hence necessitating modifications in the S2
and S19 pockets of HAV 3CP.
One of the main reasons for the low rate of success in protease
engineering has been a lack of efficient and comprehensive
screening procedures for exploring the cleavage site preferences of
engineered proteases. In this study, the task of screening the
variant library was made relatively easier by the use of the genetic
screening method, GASP. GASP has been successfully used in the
past in protease substrate specificity studies [16,26,27,]. The
current study provides further evidence that this procedure is an
efficient screening method for isolating protease variants with a
desired substrate specificity from a pool of protease variants. Other
methods that involve displaying the enzyme in a membrane to
enable it to react with exogenous synthetic substrates have also
been successfully exploited to isolate variants with a desired
substrate selectivity [28]. However, GASP in particular has been
proven to be effective for the study of cytosolic proteases. In this
Figure 5. Var26 prevents polyQ-induced cell death. A. SH-SY5Y cells were cotransfected with pcDNA-HttEx1(25Q) or (97Q)-GFP together with
an empty vector (Vec) or, pcDNA3-WT 3CP (WT), pcDNA3-Var26 (Var26), or pcDNA3-C172A (C172A). After 48 hrs of incubation, the cells were stained
with trypan blue and viewed under a microscope. Arrows indicate cells stained with trypan blue. The percentage of dead cells was plotted (n=3).
Error bars represent the SD. Significance was determined by student’s t test. *p,0.05, **p,0.01. B. In a different experiment, the same group of cells
was examined for, pyknotic nuclei by Hoechst staining. The number of pyknotic nuclei was measured and is plotted (n=3). Error bars represent the
SD. Significance was determined by student’s t test. *p,0.05, **p,0.01. C. Cells harboring the plasmids described in panel A were lysed, separated by
SDS-PAGE, and blotted and probed with a caspase-3 antibody. Tubulin was used as a loading control.
doi:10.1371/journal.pone.0022554.g005
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polyQ stretches as assayed by GASP. One of the most active
variants, Var26, prevented polyQ-induced cytotoxicity and thus
confirmed our hypothesis that the cleavage of polyQ stretch is a
valuable approach for the treatment of polyQ diseases. To ensure
that Var26 was catalytically active and that the Var26-mediated
prevention of polyQ-induced cytotoxicity was proteolytic activity-
dependent, an active site mutant of Var26, C172A, was generated.
Our results clearly show that C172A fails to rescue neuronal cells
from polyQ-induced toxicity, which indicates that the beneficial
effects of Var26 are proteolytic activity-dependent. Immunoblot-
ting showed that only a small portion of the toxic HttEx1(97Q)-
GFP protein is degraded by Var26 (Fig. 3C). Therefore, further
study of the exact molecular mechanisms underlying the effects of
Var26 is warranted.
We expected that the variant proteases would cleave anywhere
within the polyQ region, thereby making the longer aggregation-
prone polyQ stretches shorter and rendering them less susceptible
to aggregation. In this study, the variant proteases were not
directed specifically against longer polyQ stretches because our
screening assay did not discriminate the length of the polyQ
stretch. Therefore, it was quite surprising to see that the
HttEx1(25Q)-GFP protein was not affected by the presence of
Var26, while HttEx1(97Q) was substantially degraded (Fig. 3C).
We presume that this could mainly be due to structural differences
between the substrates. Because it has been previously shown that
compared to shorter polyQ stretches the longer or pathological
lengths of polyQ containing proteins undergo a length dependent
structural transition from a-helix to a b-sheet rich forms even in
their monomeric state prior to their assembly in to amyloid like
fibrils. This structural transition was shown to be critical step in the
cytotoxicity rather than the whole aggregation process itself
[29,30]. Therefore, the specificity of Var26 towards 97Q may arise
from the structural transition. Also more likely the Var26 may
attack the 97Q in its native monomeric state, a relatively more
relaxed conformer of the long polyQ during their structural
transition. The glutamine residues in the Q8 substrate expressed in
yeast as a fusion protein and the polyQ stretch in HttEx1(97Q)-
GFP may be more exposed relative to the glutamines in
HttEx1(25Q)-GFP. Whatever the difference is, this unexpected
capability of Var26 to discriminate between the substrates may
open the way for the selective degradation of pathogenic polyQ
stretch by a protease. While the proteolytic activity of Var26 and
its beneficial effects in yeast cells and mammalian cultured cells
were clearly observed, the polyQ cleaving activity of Var26 was
not detected in vitro most likely due to its low catalytic activity (data
not shown). This is understandable because some report claim that
through directed evolution as many as 50 cycles of selection were
needed to generate a protein with desired activity [31] compared
to only two cycles of selection performed in this study. Overall, it
appears that GASP is a sensitive assay and that beneficial effects
can be obtained with a protease that has relatively low polyQ
cleaving activity.
Much work remains to be done to explore the possibility of
using a modified viral protease in gene therapy for HD. The
potential for toxicity following the introduction of a viral protease
in a disease model and the effectiveness of the protease in other
polyQ disorders need to be studied. Nonetheless, this study
provides a proof-of-concept for using a polyQ-specific protease
(PQP) as a treatment for polyQ diseases. Besides broadening the
potential use of GASP as a screening method in the field of
protease engineering, this study opens-up a new window that
provides a novel insight in the development of yet unexplored
strategy to treat polyQ diseases.
Materials and Methods
Plasmid manipulation
For the yeast experiments, HAV 3CP and all of the engineered
variants were cloned into the pGAL vector as described previously
[16], and the construction of the substrate vector pADH-Ste2-Lex
has been described elsewhere [32]. The various substrate linkers
(listed in the Table S1) were cloned between the Nco1 and BamH1
sites of the substrate vector. For the mammalian cell culture work,
HAV 3CP, the engineered variant 26, and the active site mutant of
Var26 were cloned in to the EcoR1 and Xho1 sites of the
pCDNA3 vector, resulting in pcDNA3-WT 3CP, pcDNA-Var26,
and pcDNA3-C172A, respectively. The coding region of the
Human Huntingtin exon1 with 25 or 97 glutamine repeats
followed by an EGFP sequence was cloned between the Xho1 sites
of pcDNA3, resulting in pcDNA-HttEx1(25Q) or (97Q)-GFP.
Yeast transformation and screening
Yeast transformation and screening was performed as described
by Sellamuthu et al [16].
V28, M29, H145, and K146 randomization
Three sets of primers were used to make HAV 3CP in 3
fragments generated by successive PCR. Primer set STE-2-F and
V28, M29 ran-R: 59-TCC CAA GGC ATT MNN MNN CCA
TCT CAC ACA-39 was used to make fragment one. The primer
set V28, M29 ran-F: 59-TGT GTG AGA TGG NNK NNK AAT
GCC TTG GGA-39 and H145, K146 ran-R: 59-ACC ATC ATT
TTT MNN MNN AAC ATA AGT AGC-39 was used to make
fragment two. Primers H145, K146 ran-F: 59-GCT ACT TAT
GTT NNK NNK AAA AAT GAT GGT-39 and HAV3C-R were
used to generate fragment three. All of these three PCR products
were used to make the full length V28, M29, H145 and K146
randomized HAV3C proteases. The library size was one million.
M29, H145, K146, and K147 randomization
The S2 pocket residues comprising M29, H145, K146, and
K147 were randomized using the external primers STE-2-F and
HAV3C-R and two sets of randomized inner primers, (i) M29 ran-
F, 59-GTG AGA TGG GTT NNK AAT GCC TTG GGA-39; (ii)
M29 ran-R, 59-TCC CAA GGC ATT MNN AAC CCA TCT
CAC-39; (iii) HKK ran-F, 59-GCT ACT TAT GTT NNK NNK
NNK AAT GAT GGT ACA ACA-39; and (iv) HKK ran-R, 59-
TGT TGT ACC ATC ATT MNN MNN MNN AAC ATA AGT
AGC TTT-39. One million individual colonies were obtained.
L168, P169, and L199 randomization
The S19 pocket residues L168, P169, and L199 were rando-
mized to generate a mutant protease library using the set of
external primers HAV3C-F and ADH-ter-R, along with random-
ized inner primers, (i) L168, P169 ran-F: 59-AAA GGC GAA
GGT NNK NNK GGA ATG TGT GGT-39; (ii) L168, P169 ran-
R: 59-ACC ACA CAT TCC MNN MNN ACC TTC GCC TTT-
39; (iii) L199 ran-F: 59-GGA AAT TCA ATT NNK GTT GCA
AAA TTG-39; and (iv) L199 ran-R: 59-CAA TTT TGC AAC
MNN AAT TGA ATT TCC-39. A library of 70,000 colonies was
obtained.
Combining the S2 and S19 pocket mutants
Individually generated S2 and S19 pocket mutations were
combined to make the full length protease so that both S2 and S19
pocket modifications were present in the same variant. This was
performed by two-step PCR based shuffling. First, a part of the
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by PCR from the entire P2-Q substrate cleaving, S2 pocket
randomized library of variants. This included 12 candidates from
the HKKL mutants, 23 candidates from the VMHK mutants, and
19 candidates from the MHKK library (see Tables S2 and S3).
Next, a downstream fragment of the protease containing the S19
region was PCR amplified from all of the 23 candidates of the P1’-
Q substrate cleaving, S1’ pocket randomized LPL library (see
Table S4). These two individual PCR fragments, one which
contained a S2 pocket modification and the other a S19
modification, were combined and used as a template to generate
the full length protease. The final PCR product composed the
protease with modifications in both of the pockets.
Directed evolution
Variant proteases with S2 and S19 pocket mutations were
subjected to two rounds of error prone PCR (epPCR) and
shuffling. The epPCR was carried out using a Diversify PCR
random mutagenesis kit from Clontech according to the
manufacturer’s instructions. The average mutation rate was 2,3
mutations per 1000 base pairs. DNA shuffling was performed as
described by Stemmer [33].
Reagents and antibodies
Cell culture media and fetal bovine serum were purchased from
Hyclone (Logan, UT, USA) and antibiotics were purchased from
Invitrogen (Carlsbad, CA, USA). The antibodies used in this study
were as follows: a rabbit polyclonal anti-LexA DNA binding
region antibody (ab14553, Abcam, Cambridge, MA, UK); a
mouse monoclonal anti-huntingtin antibody (MAB5374, Milli-
pore, Billerica, MA, USA); a rabbit polyclonal anti-active Caspase-
3 antibody (ab13847, Abcam); and a mouse monoclonal anti-a-
tubulin antibody (sc-5286, Santa Cruz Biotechnology, Santa Cruz,
CA, USA). The HP12 antibody recognizing the first 17 amino
acids of Htt was kindly provided by Dr. Ihn Sik Seong (Harvard
Medical School). Unless otherwise mentioned, all chemicals were
purchased from Sigma.
Cell culture and transient cotransfection
SH-SY5Y human neuroblastoma cells were grown in Dulbec-
co’s modified Eagle medium supplemented with 10% fetal bovine
serum and 100 U/100 mg/ml penicillin/streptomycin. The plas-
mids pcDNA3-WT 3CP, Var26, or C172A were cotransfected
along with pcDNA3-HttEx1(25Q) or (97Q)-GFP into cells using
Lipofectamine LTX (Invitrogen). As an empty vector control, a
matching vector without an insert (pcDNA3, Invitrogen) was used.
To ensure that all cells expressing HttEx1-GFP also expressed the
appropriate protease, a 3:1 ratio of protease DNA to HttEx1-GFP
DNA was used.
Immunoblotting
For yeast cell immunoblotting, EGY48 cells grown in selective
drop out medium with either glucose or galactose/raffinose as a
carbon source were harvested by centrifugation for 2 min at room
temperature. Cells were resuspended in SUMEB buffer (1% SDS,
8 M Urea, 10 mM MOPS [pH 6.8], 10 mM EDTA, 0.01%
Bromophenol blue) containing a protease inhibitor cocktail and
were lysed by glass bead vortexing. After incubation for 10 min at
65uC, lysates were removed from the beads by centrifugation at
1,500 g for 5 min at room temperature. The supernatant was then
subjected to SDS-PAGE (10%) and transferred to PVDF
membranes (Bio-Rad Laboratories). Membranes were blocked
with 5% non-fat dry milk powder in TBS-T for 1 hr. Incubation
with the primary antibody was performed overnight at 4uC. After
incubation with peroxidase-labeled anti-mouse or anti-rabbit
antibodies (1:10,000, Zymed Laboratories), the immune complex-
es were visualized using ECL reagent (Amersham Pharmacia).
For mammalian cell immunoblotting, SH-SY5Y cells were
harvested and resuspended in lysis buffer (1% NP-40, 50 mM
Tris-HCl [pH 7.4], 150 mM NaCl, 10 mM NaF) supplemented
with a mammalian cell protease inhibitor cocktail and sonicated
briefly. The soluble protein fraction was recovered after centrifu-
gation at 10,000 g for 1 min and the supernatants were subjected to
SDS-PAGE (12%). The protein concentration was determined
using the BCA method. Protein loading was controlled by probing
for a-tubulin or GAPDH on the same membrane and the intensity
of each band was quantified by densitometry (Bio-Rad).
Immunofluorescence
SH-SY5Y cells were grown on poly-L-lysine-coated coverslips,
and after the experimental procedure, the cells were fixed with 4%
paraformaldehyde (pH 7.4)/TBS for 10 min, washed twice, and
permeabilized in 0.5% Triton X-100/TBS for 5 min at room
temperature. After three washes with TBS containing 1 mM
CaCl2 and 1 mM MgCl2, the cells were exposed to HP12
antibody for 30 min at 37uC or 1 hour at room temperature. The
fixed cells were then rinsed in TBS, incubated with Alexa 594-
conjugated secondary antibody (Invitrogen) for 30 min at 37uCo r
1 hour at room temperature and mounted in PermaFlouor
Aqueous Mountant (Lab vision Corporation). Fluorescence images
were visualized using a Leica DMRBE microscope equipped with
a 63x (1.4NA) oil objective and fluoresceine isothiocyanate- or
Texas Red-optimized filter sets (Omega
R Optical Inc, Brattleboro,
VT, USA). Images were acquired using a CoolSNAP
TMfx CCD
camera and analyzed with Metamorph imaging software (Univer-
sal Imaging Co, Downingtown, PA, USA). To determine the levels
of polyglutamine aggregation among GFP positive cells, the
number of aggregation positive cells vs the number of GFP positive
cells was counted in 40 random fields per culture.
Estimation of polyglutamine aggregation and cell death/
survival
SH-SY5Y cells were transfected with pcDNA3-HttEx1(25Q or
97Q)-GFP together with pcDNA-WT 3CP, Var26, or C172A
plasmids, and the number of dying cells was estimated by by
trypan blue staining. Cells were also examined for apoptotic
pyknotic nuclei by Hoechst staining following the methods
described by Wyttenbach et al [22], and Ye et al [34].
Supporting Information
Figure S1 Expression of Var26 is not cytotoxic. SH-SY5Y cells
were transfected with pcDNA3-WT 3CP (WT), pcDNA3-Var26
(Var26), or pcDNA3-C172A (C172A) or pcDNA-HttEx1(97Q)-
GFP. After 0, 24, 48 and 72 hours of incubation, the number of
surviving cell population was assessed by MTT assay. The
percentage of surviving cells was plotted against time. Error bars
represent the SD. Significance was determined by student’s t test.
*p,0.05.
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Table S1 Various linker sequences.
(DOCX)
Table S2 P2-Q substrate-cleaving variants selected from a
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